Cost-Effectiveness of Repository Corticotropin Injection versus Standard of Care for the Treatment of Active Rheumatoid Arthritis

References

• Zerbini CAF, Clark P, Mendez-Sanchez L, et al. Biologic therapies and bone loss in rheumatoid arthritis. Osteoporos Int. 2017;28(2):429–446. doi:10.1007/s00198-016-3769-2
   PubMed Web of Science ®Google Scholar
• Smolen JS, Aletaha D, Barton A, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018;4:18001.
   PubMed Web of Science ®Google Scholar
• Akil M, Moots R. Rheumatoid arthritis: clinical features and diagnosis. In: ABC of Rheumatology. 5th ed. Oxford: Wiley; 2018:73–76.
   Google Scholar
• Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010;376(9746):1094–1108. doi:10.1016/S0140-6736(10)60826-4
   PubMed Web of Science ®Google Scholar
• Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 2008;58(1):15–25. doi:10.1002/art.23177
   PubMed Web of Science ®Google Scholar
• Greenapple R. Trends in biologic therapies for rheumatoid arthritis: results from a survey of payers and providers. Am Health Drug Benefits. 2012;5(2):83–92.
   Google Scholar
• Arthritis Foundation. Rheumatoid arthritis treatment; 2020. Available from: https://www.arthritis.org/diseases/rheumatoid-arthritis. Accessed July 20, 2020.
   Google Scholar
• Smolen JS, Landewe R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960–977. doi:10.1136/annrheumdis-2016-210715
   PubMed Web of Science ®Google Scholar
• Singh JA, Saag KG, Bridges SL, et al. 2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2016;68(1):1–25. doi:10.1002/acr.22783
   PubMed Web of Science ®Google Scholar
• Smolen JS, Aletaha D. Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges. Nat Rev Rheumatol. 2015;11(5):276–289. doi:10.1038/nrrheum.2015.8
   PubMed Web of Science ®Google Scholar
• Taylor PC, Moore A, Vasilescu R, Alvir J, Tarallo M. A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective. Rheumatol Int. 2016;36(5):685–695. doi:10.1007/s00296-015-3415-x
   PubMed Web of Science ®Google Scholar
• Kearsley-Fleet L, Davies R, De Cock D, et al. Biologic refractory disease in rheumatoid arthritis: results from the British society for rheumatology biologics register for rheumatoid arthritis. Ann Rheum Dis. 2018;77(10):1405–1412. doi:10.1136/annrheumdis-2018-213378
   PubMed Web of Science ®Google Scholar
• Atzinger CB, Guo JJ. Biologic disease-modifying antirheumatic drugs in a national, privately insured population: utilization, expenditures, and price trends. Am Health Drug Benefits. 2017;10(1):27–36.
   PubMed Web of Science ®Google Scholar
• Desai RJ, Solomon DH, Jin Y, Liu J, Kim SC. Temporal trends in use of biologic DMARDs for rheumatoid arthritis in the United States: a cohort study of publicly and privately insured patients. J Manag Care Spec Pharm. 2017;23(8):809–814. doi:10.18553/jmcp.2017.23.8.809
   Web of Science ®Google Scholar
• Bijlsma JW, Boers M, Saag KG, Furst DE. Glucocorticoids in the treatment of early and late RA. Ann Rheum Dis. 2003;62(11):1033–1037. doi:10.1136/ard.62.11.1033
   Web of Science ®Google Scholar
• Mallinckdrodt Pharmaceuticals. Acthar® Gel [package insert]. New Jersey, USA: Mallinckdrodt Pharmaceuticals H; February 2021.
   Google Scholar
• Catania A, Lonati C, Sordi A, Carlin A, Leonardi P, Gatti S. The melanocortin system in control of inflammation. ScientificWorldJournal. 2010;10:1840–1853. doi:10.1100/tsw.2010.173
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Furst DE, Connolly-Strong E, Liu J, Zhu J, Brasington R. Repository corticotropin injection for active rheumatoid arthritis despite aggressive treatment: a randomized controlled withdrawal trial. Rheumatol Ther. 2020;7(2):327–344. doi:10.1007/s40744-020-00199-3
   PubMed Web of Science ®Google Scholar
• Ho-Mahler N, Turner B, Eaddy M, Hanke ML, Nelson WW. Treatment with repository corticotropin injection in patients with rheumatoid arthritis, systemic lupus erythematosus, and dermatomyositis/polymyositis. Open Access Rheumatol. 2020;12:21–28. doi:10.2147/OARRR.S231667
   PubMed Web of Science ®Google Scholar
• Wu B, Deshpande G, Gu T, Popelar B, Philbin M, Wan GJ. Demographics, treatment patterns, and healthcare utilization and cost of repository corticotropin injection in patients with systemic lupus erythematosus or rheumatoid arthritis. J Med Econ. 2017;20(11):1170–1177. doi:10.1080/13696998.2017.1362411
   PubMed Web of Science ®Google Scholar
• van der Heijde DM, van ‘T Hof MA, van Riel PL, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis. 1990;49(11):916–920. doi:10.1136/ard.49.11.916
   PubMed Web of Science ®Google Scholar
• van der Kooi E, Klarenbeek NB, Guler-Yuksel M, et al. A decrease in disease activity score (DAS) level is associated with a decrease in health assessment questionnaire (HAQ) score, independent of follow-up duration, during 5 years of tightly controlled treatment: results from the BeSt study. Ann Rheum Dis. 2011;70(1):168–171. doi:10.1136/ard.2010.133132
   Web of Science ®Google Scholar
• Kim HL, Kim D, Jang EJ, et al. Mapping health assessment questionnaire disability index (HAQ-DI) score, pain visual analog scale (VAS), and disease activity score in 28 joints (DAS28) onto the EuroQol-5D (EQ-5D) utility score with the KORean observational study network for arthritis (KORONA) registry data. Rheumatol Int. 2016;36(4):505–513. doi:10.1007/s00296-016-3427-1
   Web of Science ®Google Scholar
• Onuoha KO, Solow M, Newman JM, et al. Have the annual trends of total hip arthroplasty in rheumatoid arthritis patients decreased? Ann Transl Med. 2017;5(Suppl 3):S35. doi:10.21037/atm.2017.11.15
   Web of Science ®Google Scholar
• Clair AJ, Evangelista PJ, Lajam CM, Slover JD, Bosco JA, Iorio R. Cost analysis of total joint arthroplasty readmissions in a bundled payment care improvement initiative. J Arthroplasty. 2016;31(9):1862–1865. doi:10.1016/j.arth.2016.02.029
   Web of Science ®Google Scholar
• Boonstra AM, Schiphorst Preuper HR, Balk GA, Stewart RE. Cut-off points for mild, moderate, and severe pain on the visual analogue scale for pain in patients with chronic musculoskeletal pain. Pain. 2014;155(12):2545–2550. doi:10.1016/j.pain.2014.09.014
   PubMed Web of Science ®Google Scholar
• Lalonde L, Choiniere M, Martin E, Berbiche D, Perreault S, Lussier D. Costs of moderate to severe chronic pain in primary care patients - a study of the ACCORD program. J Pain Res. 2014;7:389–403. doi:10.2147/JPR.S55388
   PubMed Web of Science ®Google Scholar
• Day AL, Curtis JR. Opioid use in rheumatoid arthritis: trends, efficacy, safety, and best practices. Curr Opin Rheumatol. 2019;31(3):264–270. doi:10.1097/BOR.0000000000000602
   PubMed Web of Science ®Google Scholar
• Lee YC, Kremer J, Guan H, Greenberg J, Solomon DH. Chronic opioid use in rheumatoid arthritis: prevalence and predictors. Arthritis Rheumatol. 2019;71(5):670–677. doi:10.1002/art.40789
   PubMed Web of Science ®Google Scholar
• White AG, Birnbaum HG, Mareva MN, et al. Direct costs of opioid abuse in an insured population in the United States. J Manag Care Pharm. 2005;11(6):469–479. doi:10.18553/jmcp.2005.11.6.469
   PubMedGoogle Scholar
• Bureau of Labor Statistics. National occupational employment and wage estimates United States; 2019. Available from: https://www.bls.gov/oes/current/oes_nat.htm#00-0000. Accessed September 13, 2020.
   Google Scholar
• Birnbaum HG, Ivanova JI, Samuels S, et al. Economic impact of multiple sclerosis disease-modifying drugs in an employed population: direct and indirect costs. Curr Med Res Opin. 2009;25(4):869–877. doi:10.1185/03007990902743869
   PubMed Web of Science ®Google Scholar
• Stevenson M, Archer R, Tosh J, et al. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation. Health Technol Assess. 2016;20(35):1–610.
   Web of Science ®Google Scholar
• Hernandez Alava M, Wailoo AJ, Ara R. Tails from the peak district: adjusted limited dependent variable mixture models of EQ-5D questionnaire health state utility values. Value Health. 2012;15(3):550–561. doi:10.1016/j.jval.2011.12.014
   PubMed Web of Science ®Google Scholar
• Dubois RW. Cost-effectiveness thresholds in the USA: are they coming? Are they already here? J Comp Eff Res. 2016;5(1):9–11. doi:10.2217/cer.15.50
   PubMed Web of Science ®Google Scholar
• Institute for Clinical and Economic Review. 2020–2023 value assessment framework; 2020.
   Google Scholar
• Porter ME. What is value in health care? N Engl J Med. 2010;363(26):2477–2481. doi:10.1056/NEJMp1011024
   PubMed Web of Science ®Google Scholar
• International Business Machines. Micromedex® RED BOOK; 2020. Available from: https://www.micromedexsolutions.com/home/dispatch/ssl/true. Accessed November 20, 2020.
   Google Scholar
• ClinicaTrials.gov (NCT02919761). Safety and effectiveness of acthar gel in participants with rheumatoid arthritis; 2020. Available from: https://clinicaltrials.gov/ct2/show/NCT02919761. Accessed July 20, 2020.
   Google Scholar
• Eisenberg Center at Oregon Health & Science University. Choosing medications for rheumatoid arthritis: clinician’s guide. In: Comparative Effectiveness Review Summary Guides for Clinicians. Rockville, MD; 2007.
   Google Scholar
• Klimes J, Vocelka M, Sedova L, et al. Medical and productivity costs of rheumatoid arthritis in the Czech Republic: cost-of-illness study based on disease severity. Value Health Reg Issues. 2014;4:75–81. doi:10.1016/j.vhri.2014.07.004
   PubMedGoogle Scholar
• Myung G, Nelson WW, McMahon MA. Effects of repository corticotropin injection on medication use in patients with rheumatologic conditions: a claims data study. J Pharm Technol. 2017;33(4):151–155. doi:10.1177/8755122517709825
   PubMed Web of Science ®Google Scholar